Divergence from Classical Topoisomerase IIβ Cleavage: Ferroptotic Rupture in Anthracycline Myopathy
The clinical management of anthracycline chemotherapy has long centered on TOP2B-mediated DNA double-strand breaks as the primary driver of cardiac injury [1]. However, clinical regimens producing plasma concentrations between 0.2 μM and 1.0 μM trigger early cytotoxic kinetics that do not align with classical apoptosis [1][2]. In HL-1 murine atrial cardiomyocytes and H9c2 rat cardiomyoblasts, challenge with 0.5 μM doxorubicin induces pronounced cell detachment and viability loss within 16 to 24 hours [2][3]. Co-administration of the pan-caspase antagonist Z-VAD-FMK at concentrations up to 50 μM fails to reverse cell death, whereas lipophilic radical-trapping antioxidants such as Ferrostatin-1 (1 μM to 5 μM) or Liproxstatin-1 (200 nM to 1 μM) confer near-complete cytoprotection [2][3]. Similarly, suppressing necroptosis using Necrostatin-1 or targeting pyroptosis fails to mitigate early troponin release in cultured cardiomyocytes [2].
Transmission electron microscopy of left ventricular biopsies derived from doxorubicin-treated rodents displays canonical ferroptotic morphology [1][2]. Affected cardiomyocytes exhibit diminished mitochondrial volume, condensed and disrupted outer mitochondrial membranes, and vanishing cristae, while maintaining structurally intact nuclear envelopes devoid of apoptotic peripheral chromatin condensation [1][2]. This distinct cytopathology stems from accelerated membrane lipid peroxidation rather than endonucleolytic DNA fragmentation [1]. Comparative molecular profiling under standardized anthracycline exposure establishes distinct mechanistic boundaries between ferroptosis, caspase-dependent apoptosis, and necroptosis in cardiac tissue, as summarized in Table 1 below.
ACSL4-Catalyzed Esterification of Polyunsaturated Fatty Acids in the Cardiac Sarcoplasm
The commitment of cardiomyocytes to ferroptosis is governed by the structural remodeling of sarcoplasmic phospholipid bilayers [1][4]. Acyl-CoA synthetase long-chain family member 4 (ACSL4) functions as the key enzyme initiating this cascade by esterifying free polyunsaturated fatty acids (PUFAs) with coenzyme A [1][4]. ACSL4 displays strict substrate specificity toward arachidonic acid (C20:4, \u03c9-6) and adrenic acid (C22:4, \u03c9-6), exhibiting Km values below 5 μM for these long-chain polyunsaturates [1]. Upon anthracycline exposure, ACSL4 undergoes rapid transcriptional and post-translational upregulation in myocardial tissue within 6 to 12 hours [1][5]. In AC16 human cardiomyocyte models, doxorubicin exposure at 1 μM produces a three- to fourfold induction of ACSL4 protein expression, directly accelerating the esterification rate of free arachidonate into arachidonoyl-CoA [5].
Following ACSL4-dependent activation, lysophospholipid acyltransferase 3 (LPLAT3/LPCAT3) incorporates arachidonoyl-CoA and adrenoyl-CoA intermediates into membrane glycerophospholipids, predominantly phosphatidylethanolamines (PE) [1]. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) lipidomic profiling reveals that cardiac sarcoplasmic membranes accumulate substantial amounts of 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (PE-18:0/20:4) within 12 hours of doxorubicin challenge [1][5]. These sn-2 esterified polyunsaturated moieties feature readily accessible bis-allylic methylene carbons that possess low carbon-hydrogen bond dissociation energies (~322 kJ/mol) [1]. Consequently, the selective enrichment of PE-arachidonoyl species catalyzed by ACSL4 provides the obligate chemical substrate required for non-enzymatic and enzymatic autoxidation chains, rendering the cardiac sarcolemma vulnerable to biophysical collapse [1][4].
Acot1 Depletion Eliminates Free Fatty Acid Shunting and Elevates the Acyl-CoA Precursor Pool
Under normal physiological conditions, the heart relies on long-chain fatty acid β-oxidation to meet high baseline energetic demands [6][7]. Cytosolic acyl-CoA thioesterase 1 (Acot1) acts as a critical counter-regulatory metabolic valve by hydrolyzing fatty acyl-CoAs back into free fatty acids and coenzyme A [1][7]. By cleaving long-chain substrates, Acot1 prevents the abnormal accumulation of intracellular acyl-CoA pools and restricts unnecessary lipid intermediate incorporation into cellular structural membranes [6][7]. However, myocardial tissue challenged with therapeutic concentrations of doxorubicin exhibits a steep, progressive decline in Acot1 mRNA and protein expression [1][6]. In murine ventricles, single-dose doxorubicin administration (15 mg/kg) provokes a marked loss of cardiac Acot1 expression within 24 hours [6].
The loss of Acot1 activity halts the cytosolic acyl-CoA hydrolysis shunt [1][7]. Deprived of Acot1-mediated cleavage, arachidonoyl-CoA and adrenoyl-CoA intermediates avoid metabolic degradation and accumulate unchecked in the sarcoplasm [1][6]. This sustained elevation of the acyl-CoA precursor pool exerts mass-action pressure directly toward membrane esterification pathways [1]. Knockdown of Acot1 via targeted small interfering RNA in neonatal cardiomyocytes exacerbates doxorubicin sensitivity, elevating basal lipid peroxidation and precipitating spontaneous ferroptotic rupture [6][7]. Conversely, forcing Acot1 expression preserves cellular viability, proving that Acot1 suppression acts synergistically with ACSL4 activation to fuel toxic phospholipid assembly [1][6].
Mitochondrial Labile Iron Expansion and Iron-Catalyzed Peroxidation Chains
The metabolic accumulation of polyunsaturated phosphatidylethanolamines requires an iron-dependent catalyst to execute membrane peroxidation [1][2]. Doxorubicin possesses a planar hydroxyanthraquinone aglycone ring system capable of univalent electron reduction [1]. Inside the cardiomyocyte sarcoplasm and mitochondrial inner membrane, electron transport chain Complex I and NAD(P)H oxidoreductases transfer electrons to the doxorubicin quinone nucleus, producing a reactive semiquinone radical intermediate [1]. Under aerobic conditions, this semiquinone autoxidizes by transferring its acquired electron to molecular oxygen, generating superoxide anions (\uce{O2^{\u2022-}}) and regenerating the parent quinone core to sustain redox cycling [1].
Superoxide dismutation produces excessive hydrogen peroxide (\uce{H2O2}), which degrades ferritin complexes and mitochondrial heme-containing proteins, elevating sarcoplasmic labile iron (\uce{Fe^2+}) levels [1][6]. The expanded \uce{Fe^2+} pool coordinates with doxorubicin molecules, assembling ternary drug-iron-membrane complexes adjacent to polyunsaturated fatty acyl chains [1]. Through classical Fenton chemistry, \uce{Fe^2+} reacts with \uce{H2O2} to form highly destructive hydroxyl radicals (\uce{^{\u2022}OH}), which perform bis-allylic hydrogen abstraction on PE-arachidonoyl species [1][2]. The resulting carbon-centered phospholipid radicals capture molecular oxygen to produce phospholipid peroxyl radicals (\uce{PL-OO^{\u2022}}), triggering sustained auto-catalytic propagation [1]. In tandem, doxorubicin causes marked depletion of glutathione peroxidase 4 (GPX4) and downregulates the cystine/glutamate antiporter SLC7A11 [1][7]. The secondary collapse of GPX4 halts the reduction of toxic phospholipid hydroperoxides (\uce{PL-OOH}) into harmless phospholipid alcohols (\uce{PL-OH}), driving irreversible sarcolemmal pore formation [1].
Pharmacological Reversal Through Targeted Lipid Editing and Enzyme Modulation
Mitigating doxorubicin-induced cardiotoxicity requires pharmacological strategies that decouple ACSL4 activation or re-establish acyl-CoA hydrolysis [1][6]. In C57BL/6 male mice subjected to acute cardiotoxic regimens (20 mg/kg intraperitoneally), targeted pharmacological suppression of ACSL4 using small-molecule antagonists such as PRGL493 (10 mg/kg) or Rosiglitazone (10 mg/kg) reduces myocardial malondialdehyde (MDA) adducts by more than 50% [4][5]. Rosiglitazone acts as a competitive ACSL4 inhibitor, preventing arachidonoyl-CoA formation and attenuating doxorubicin-induced left-ventricular ejection fraction (LVEF) deterioration [5]. In cultured cardiomyocytes, ACSL4 inhibition restores cell survival, demonstrating that halting polyunsaturated fatty acid esterification blocks downstream membrane degradation [4][5].
Genetic complementation strategies that re-establish acyl-CoA homeostasis further confirm this therapeutic logic [1][6]. Delivering human Acot1 via cardiotropic adeno-associated virus serotype 9 (AAV9) under control of the cardiac troponin T promoter prevents toxic acyl-CoA accumulation in treated rodents [2][6]. Rescuing Acot1 activity suppresses C11-BODIPY 581/591 fluorophore oxidation and maintains normal sarcoplasmic reticulum calcium handling [3][6]. By comparison, dexrazoxane—the only clinically approved cardioprotectant against anthracyclines—acts downstream via intracellular iron chelation and topoisomerase IIβ antagonism [6]. Direct genetic or chemical disruption of the ACSL4-Acot1 axis prevents the synthesis of peroxidation substrates at the source, offering cardioprotection that shields myocardial structural integrity without blunting the chemotherapeutic efficacy of doxorubicin [1][6].